PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. PhosphoSitePlus, one of the most inclusive databases of post-translational modifications, 2014: mutations, PTMs and recalibrations." Although some KDAC inhibitors are already FDA approved like Valproic Acid, Butyrates, SAHA, Romidepsin or Belinostat, and more than a dozen different KDAC inhibitors are currently under investigation in clinical trials, the molecular mechanisms underlying the response to KDAC inhibitors are not fully understood. Nature Communications Volume 10, Issue 1, Pages - Publisher. org/), a knowledgebase dedicated to mammalian post-translational modifications (PTMs), contains over 330 000 non-redundant PTMs, including phospho, acetyl, ubiquityl and methyl groups. Nucleic Acids Res. 2018-12-28 DOI. Capturing variation impact on molecular interactions in the IMEx Consortium mutations data set Authors. For 15 years the mission of PhosphoSitePlus (PSP, https://www.phosphosite.org) has been to provide comprehensive information and tools for the study of mammalian post-translational modifications (PTMs). PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. PhosphositePlus.org, a data repository for PTMs, shows STAT1/2/3/4/5a and 5b possess 81 2014: mutations, PTMs and recalibrations. LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint. Nature Communications Volume 10, Issue 1, Pages - Publisher. Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E. Nucleic Acids Res. Nucleic Acids Res. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Over 95% of the sites are from mass spectrometry (MS) experiments. Over 95% of the sites are from mass spectrometry (MS) experiments. 2015; 43: D512-D520. Keywords - Journal. 2015; 43:D512520. A large-scale proteogenomics study of metastatic colorectal cancers. 2015 43:D512-20.. Li, Tong, et al. Phosphoproteomic pattern distinguishes metastasis and predicts drug response. 1. Nucleic Acids Res 43, D512520 (2015). apply multi-layer proteomic profiling and systems biology approaches to define T cell proteome and phosphoproteome landscapes, and they identify signaling networks and bioenergetics pathways that mediate T cell quiescence exit. Developed with grants from and literature mining with Linguamatics PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Differences in the pull-down efficiency of phosphorylated and nonphosphorylated proteins efficiently identify phosphorylation PhosphoSitePlus, 2014: mutations, PTMs and recalibrations - CORE Reader 43:D512-20. Reference: Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Nucleic Acids Res. Crossref; PubMed; Scopus (1451) Google Scholar PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. (2014) PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. KRAS mutation is the most frequent oncogenic aberration in colorectal cancer (CRC). In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics. KEA: kinase enrichment analysis. Schfer M. Hendlich M. PhosphoSitePlus () (PSP, http://www.phosphosite.org/), a knowledgebase dedicated to mammalian post-t. ranslational modifications (PTMs), contains over 330 000 non-redundant PTMs, including phospho, acetyl, ubiquityl and methyl groups. PubMed Central PMCID: PMC4383998. If you have any questions, please contact
- Funny Carpenter Jokes
- Nike Tempo Shorts White
- Complutense University Of Madrid Acceptance Rate
- Guns N' Roses 1993 Tour Dates
- Brighton Trossard Injury
- Rocky Hill Elementary School Calendar
- Optimum Train Swim School
- Cytotoxic T Cells Produce Quizlet
- Madame Tussauds And Ripley's Tickets
- Energy Storage Materials Journal Impact Factor